Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells

Abstract

IntroductionWe investigated Nestin expression in triple-negative breast cancer and examined how the modulation of Nestin expression affects cell cycle progression, survival, invasion and regulatory signaling in breast cancer stem cells (CSC) in vitro.MethodsNestin expression in 150 triple-negative breast cancer specimens were examined by immunohistochemistry. The role of Nestin expression in tumorigenesis was examined by assaying naturally occurring Nestinhigh/Nestinlow CSC from 12 breast cancer tissues, as well as CSC from 26 clinical specimens, where Nestin overexpression and silencing was achieved by genetic manipulation, for their ability to form mammospheres and induce solid tumors. Cell cycle progression, spontaneous apoptosis and invasiveness of Nestin-silenced breast CSC were investigated by flow cytometry and transwell assays. The relative levels of expression of epithelial-mesenchymal transition (EMT) and Wnt/β-catenin pathway-related molecules were determined by western blotting.ResultsNestin expression was significantly associated with poor survival in patients with triple-negative breast cancer (P = 0.01). Nestinhigh breast CSC rapidly formed typical mammospheres in vitro. Nestinhigh, but not Nestinlow CSC, efficiently formed solid tumors in vivo. Nestin silencing induced cell cycle arrest at G2/M (52.03% versus 19.99% in controls) and promoted apoptosis (36.45% versus 8.29% in controls). Nestin silencing also inhibited breast CSC invasiveness, and was associated with significantly upregulated E-cadherin, while N-cadherin, vimentin, a-smooth muscle actin (a-SMA), matrix metalloproteinase-2 (MMP-2), MMP-9 and vascular endothelial growth factor (VEGF) expression was downregulated (P <0.05 for all). Nestin silencing also upregulated Axin, glycogen synthase kinase-3 beta (GSK-3β), adenomatous polyposis coli (APC), and peroxisome proliferator-activated receptor alpha (PPARa), and downregulated β-catenin, c-Myc, cyclin D and MMP-7 expression in CSC. Inhibition of the Wnt/β-catenin pathway mitigated mammosphere formation in Nestinhigh CSC, while inhibition of GSK-3β promoted the mammosphere formation in Nestinlow CSC (P <0.05 for all).ConclusionsOur data indicates that Nestin positively regulates the proliferation, survival and invasiveness of breast CSC by enhancing Wnt/β-catenin activation.Electronic supplementary materialThe online version of this article (doi:10.1186/s13058-014-0408-8) contains supplementary material, which is available to authorized users.

Expression of B-cell translocation gene 2 is associated with favorable prognosis in hepatocellular carcinoma patients and sensitizes irradiation-induced hepatocellular carcinoma cell apoptosis in vitro and in nude mice

“…Several previous studies have reported that BTG2 expression was reduced in various human cancers including renal cell carcinoma, prostate cancer, gastric cancer, melanoma, breast cancer and lung cancer (8,(16)(17)(18)(19)(20). Further studies also revealed that BTG2 expression was reversely associated with tumor grade, size, metastasis, recurrence and survival in breast cancer (8,28). Consistent with these studies, the results from the present study also revealed markedly downregulated BTG2 expression in hepatoma tissues.…”

Salinomycin inhibits canine mammary carcinoma in vitro by targeting cancer stem cells

“…A previous study has identified that this signaling pathway is upregulated in human breast CSCs (28). Similar to in humans, the present study revealed that stem cell-like spheres overexpressed the Wnt/β-catenin signaling pathway-associated proteins β-catenin and Cyclin D1, indicating that this signaling pathway is also upregulated in canine mammary CSCs.…”

Promoter methylation and expression of Raf kinase inhibitory protein in esophageal squamous cell carcinoma

“…During cancer development, RKIP is characterized as a tumor suppressor gene because of its maintenance of chromosome stability, inhibition of cellular proliferation, promotion of cell differentiation and dynamic balancing of oncogene activities (11). Consistently, previous studies have reported RKIP absence or downregulation and its clinical significance in a variety of human cancers, such as prostate, breast and gastric cancers (12)(13)(14). These observations led to intensive studies on the mechanisms and functions of RKIP in cancers; however, few previous studies have analyzed the RKIP methylation and expression status in ESCC.…”